Evolving landscape of first-line combination therapy in advanced renal cancer: a systematic review.
Aly-Khan A LalaniDaniel Y C HengNaveen S BasappaLori WoodNayyer IqbalDeanna McLeodDenis SoulièresChristian KollmannsbergerPublished in: Therapeutic advances in medical oncology (2022)
Phase III first-line trials of ICI combinations showed survival benefits compared with a control arm of sunitinib. Global access to these combinations should be made available to patients with advanced RCC.